Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors
NCT05415475Phase 1Completed
- Sponsor
- Chongqing Precision Biotech
- Start
- Sep 2021
- Primary completion
- Jun 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CEA CAR-T cells in solid tumor, colorectal cancer (CRC), esophageal cancer and 2 more (2 arms), sponsored by Chongqing Precision Biotech. Primary endpoints: Incidence of Adverse Events at 28 days and Maximum Tolerated Dose at 28 days. Started Sep 2021; status: completed.
02
Drugs
CEA CAR-T cells
03
Conditions
solid tumorcolorectal cancer (CRC)esophageal cancergastric cancer (GC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05415475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05415475.